Screener
Bicara Therapeutics BCAX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and Contingencies (Note 7) | ||
| Stockholders' equity: | ||
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value, 500,000,000 and 500,000,000 shares authorized; 65,547,037 and 56,600,724 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 8 | 7 |
| Additional paid-in capital | 929,370 | 760,168 |
| Accumulated other comprehensive (loss) income | (243) | 243 |
| Accumulated deficit | (415,177) | (358,966) |
| Total stockholders' equity | 513,958 | 401,452 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's common stock?
- Bicara Therapeutics (BCAX) reported common stock of 500M in Q1 2026.
- How has Bicara Therapeutics's common stock changed year-over-year?
- Bicara Therapeutics's common stock decreased by 0.0% year-over-year, from 500M to 500M.
- What is the long-term trend for Bicara Therapeutics's common stock?
- Over 2 years (2023 to 2025), Bicara Therapeutics's common stock has grown at a 49900.0% compound annual growth rate (CAGR), from 2K to 500M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Bicara Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude